# Cytotoxic half-sandwich rhodium(III) complexes: Polypyridyl ligand influence on their DNA binding properties and cellular uptake 

Michael A. Scharwitz ${ }^{\text {a }}$, Ingo Ott ${ }^{\text {b }}$, Yvonne Geldmacher ${ }^{\text {a }}$, Ronald Gust ${ }^{\text {b }}$, William S. Sheldrick ${ }^{\text {a,* }}$<br>${ }^{\text {a }}$ Lehrstuhl für Analytische Chemie, Ruhr-Universität Bochum, Universitätsstrasse 150, D-44780 Bochum, Germany<br>${ }^{\mathrm{b}}$ Institut für Pharmazie, Freie Universität Berlin, Königin-Luise-Straße 2-4, D-14195 Berlin, Germany

## A R T I C L E I N F O

## Article history:

Received 12 February 2008
Received in revised form 1 April 2008
Accepted 2 April 2008
Available online 6 April 2008

## Keywords:

Bioorganometallic chemistry
Rhodium
Polypyridyl ligands
DNA binding
Cytotoxicity
Cellular uptake


#### Abstract

The DNA binding of polypyridyl (pp) $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ complexes of the types $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{pp})\right]-$ $\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{2 - 6})\left(\mathrm{pp}=\mathrm{bpy}\right.$, phen, dpq, dppz, dppn), $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}$ (7-9) (pp = dpq, dppz, dppn) and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) R h(\mathrm{~L})(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{1 0})\left(\mathrm{L}=\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}^{-}\right)$and (11) $\left(\mathrm{L}=\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}^{-}\right)$has been studied by UV/Vis spectroscopy, circular dichroismus and viscosity measurements. Complexes 3-11 are cytotoxic towards the human MCF-7 breast and HT-29 colon cancer cell lines and exhibit $\mathrm{IC}_{50}$ values in the range $0.56-10.7 \mu \mathrm{M}$. Stable intercalative binding into CT-DNA is indicated for the dpq and dppz complexes by large increases $\Delta T_{\mathrm{m}}$ of 6-12 ${ }^{\circ} \mathrm{C}$ in the DNA thermal denaturation temperature for $r=$ [complex]/[DNA] $=0.1$ and by induced CD bands and large viscosity increases. In contrast, significant DNA lengthening is not observed after incubation of the biopolymer with the dppn complexes $\mathbf{2}$ and 9 at molar ratios of $r<0.08$. Pronounced hypochromic shifts for the $\pi-\pi^{*}$ transitions of the dppn ligands in the range 320-425 nm indicate the possible presence of surface stacking. The in vitro cytotoxicities of the chloro complexes 4-6 and the $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ complexes $\mathbf{7 - 9}$ are dependent on the size of the polypyridyl ligand with $\mathrm{IC}_{50}$ values decreasing in the order $\mathrm{dpq}>\mathrm{dppz}>\mathrm{dppn}$. For instance, $\mathrm{IC}_{50}$ values of $5.3,1.5$ and $0.91 \mu \mathrm{M}$ were determined for $\mathbf{7 - 9}$ against MCF-7 cells. Rapid $\mathrm{Cl}^{-} / \mathrm{H}_{2} \mathrm{O}$ exchange leads the formation of aqua dications for 4-6, whose levels of cellular uptake and cytotoxicities are similar to those established for 7-9. Intramolecular interactions between the aromatic thiolate and dppz ligands of $\mathbf{1 0}$ and 11 prevent significant DNA intercalation. X-ray structural determinations have been performed for 2-7 and 11.


© 2008 Elsevier B.V. All rights reserved.

## 1. Introduction

Organometallic compounds containing the Group 8 elements iron and ruthenium are attracting considerable current interest as potential anticancer agents [1-3]. For instance, ferrocifen, a ferrocenyl derivative of tamoxifen, exhibits promising antitumour activity and is a possible candidate for clinical trials [4]. Half-sandwich ( $\eta^{6}$-arene) $\mathrm{Ru}^{\text {II }}$ complexes with imidazole [5], sulfoxide [6-8], phosphane [3,9], chelating amino acidato [10], and diamine or diimine ligands [2,11] have also been evaluated for cytotoxic activity. Such studies have recently been extended to analogous ( $\eta^{6}$-arene) $\mathrm{Os}^{\text {II }}$ compounds [12-14].

Both the size of the arene and the lability of the $\mathrm{Ru}-\mathrm{Cl}$ bond have found to play a crucial role in determining the cytotoxicity of ruthenium(II) complexes of the type $\left[\left(\eta^{6}\right.\right.$-arene $\left.) \mathrm{RuCl}\left(\mathrm{LL}^{\prime}\right)\right]\left(\mathrm{PF}_{6}\right)$ with bidentate ligands LL'. Compounds with extended polycyclic arenes (e.g. tetrahydroanthracene) and $\mathrm{LL}^{\prime}=$ ethylenediamine (en) are most active towards A2780 human ovarian cancer cells,

[^0]whereas those with polar substituents on the arene or with aromatic diimine ligands such as $2,2^{\prime}$-bipyridine (bpy) or $1,10-$ phenanthroline (phen), exhibit either poor or no activity [2]. Further increases in the size of the polypyridyl ligand (pp) lead, however, to a dramatic reversal of the latter trend and the in vitro cytotoxicities of the complexes $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{RuCl}(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ towards the human cell lines HT-29 (colon cancer) and MCF-7 (breast cancer) are strongly dependent on the surface area of the aromatic system [15]. For instance, the $\mathrm{IC}_{50}$ values decreases from 11.1 over 2.12 to $0.13 \mu \mathrm{M}$ for MCF-7 cells as the size of the polypyridyl ligand increases in the order $\mathrm{dpq}<\mathrm{dppz}<\mathrm{dppn} \quad(\mathrm{dpq}=$ dipyrido-[3,2-f: $\left.2^{\prime}, 3^{\prime}-h\right] q u i n o x a l i n e ; ~ d p p z=d i p y r i d o\left[3,2-a: 2^{\prime}, 3^{\prime}-c\right]$ phenazine; dppn $=$ benzo $i$ ] dipyrido $\left[3,2-a: 2^{\prime}, 3^{\prime}-c\right]$ phenazine $)$. These values correlate well with the cellular uptake efficiency, which increases from 1.1 over 146.6 to $906.7 \mathrm{ng}(\mathrm{Ru}) / \mathrm{mg}$ (protein) within the series [15]. The kinetically inert complexes $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}\left\{\left(\mathrm{NH}_{2}\right)_{2} \mathrm{CS}\right\}\right.$ (pp)]( $\left.\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}(\mathrm{pp}=\mathrm{dppz}, \mathrm{dppn})$ are also cytotoxic and this suggests that specific properties of the large polypyridyl ligands (e.g. DNA intercalation [16,17] and/or cleavage [18]) may be responsible for their biological activity. DNA binding studies indicate that $\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}^{\text {II }}$ compounds containing dpq or particularly dppz
ligands are good metallointercalators but that the dppn ligand is too large to support stable intercalation between the base pairs of the double helix [15].

In striking contrast to their Group 8 neighbours, half-sandwich complexes of the Group 9 transition metals rhodium(III) and iridium(III) have attracted little interest as potential anticancer agents. An in vitro evaluation of the RAPTA analogues $\left[\left(\eta^{6}-p\right.\right.$-cymene $\left.) \mathrm{RhCl}_{2}(\mathrm{pta})\right], \quad\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}_{2}(\mathrm{pta})\right]$ and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}-\right.$ (pta) $)_{2}$ ]Cl (pta $=$ 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane) towards HT-29, A549 (lung carcinoma) and T47D (breast carcinoma) cells has recently been appeared [14], but the reported high $\mathrm{IC}_{50}$ values ( $\geqslant 380 \mu \mathrm{M}$ ) are indicative of very limited cytotoxicity. In contrast, much lower $\mathrm{IC}_{50}$ values of, respectively, 7.4 and $0.41 \mu \mathrm{M}$ have recently reported [15] for the [( $\left.\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right)$ )r ${ }^{\text {III }}$ complexes $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{IrCl}(\mathrm{dppz})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Ir}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2}-\right.\right.$ $\mathrm{CS}\}(\mathrm{dppn})]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}$ [19] towards HT-29 cells. Interestingly, the increased lability of the $\mathrm{Ir}-\mathrm{Cl}$ bond in the former complex leads to thermodynamically favoured coordinative $\mathrm{Ir}-\mathrm{N}$ (nucleobase) binding to DNA rather than intercalation, as observed for the analogous ( $\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}$ ) Ru' ${ }^{\text {II }}$ complex [15]. We now report DNA binding studies and evaluations of the in vitro cytotoxicity of polypyridyl half-sandwich $\mathrm{Rh}^{\text {III }}$ complexes of the types $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{pp})\right]$ $\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ (Scheme 1), $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}$ ( $\mathrm{pp}=\mathrm{dpq}$, dppz, dppn) (Scheme 2) and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{L})(\mathrm{dppz})\right]$ $\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)\left(\mathrm{L}=\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}^{-}, \mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}^{-}\right)$(Scheme 3). Two factors may be expected to possibly modify the biological properties of such $\mathrm{Rh}^{\mathrm{II}}$ compounds with respect to analogous half-sandwich $\mathrm{Ir}^{\text {III }}$ or $\mathrm{Ru}^{\text {II }}$ complexes: (a) the increase in the rate of chloride substitution in the order $\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}^{\text {II }} \ll\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{II}^{\text {III }}<\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ [20] and (b) the pronounced softness of the third-row transition metal Ir $^{\text {III }}$ in comparison to $\mathrm{Ru}^{\text {II }}$ or $\mathrm{Rh}^{\text {III }}$, owing to relativistic destabilisation of its 5d shell [21].

## 2. Results and discussion

### 2.1. Synthesis of 1-11

The compounds of the type $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{en})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{1})$ and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{2 - 6})(\mathrm{pp}=\mathrm{bpy}$, phen, dpq, dppz, dppn) were synthesised by heating the solvent complex $\left.\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl} \text { (acetone }\right)_{2}\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ with the appropriate polypyridyl ligand (pp) at $75^{\circ} \mathrm{C}$ in $\mathrm{CH}_{3} \mathrm{OH} / \mathrm{CH}_{2} \mathrm{Cl}_{2}$ for 2 h . $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right)\right.$ $\left.\mathrm{RhCl}(\text { acetone })_{2}\right]^{+}$was prepared in situ by addition of two equivalents of $\mathrm{Ag}\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ to a solution of the dinuclear starting compound $\left[\left\{\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}\right\}_{2}(\mu-\mathrm{Cl})_{2}\right]$ in acetone and subsequent filtration of precipitated AgCl after stirring in the dark for 0.5 h . Following removal of the remaining chloride by analogous treatment of complexes 4-6 with an equivalent of $\mathrm{Ag}\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ in acetone, addition of tetramethyl thiourea $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ to the resulting in situ complex


Scheme 1. Structures of complexes 2-6.


Scheme 2. Structures of complexes 7-9.


Scheme 3. Structures of complexes 10 and 11.
$\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\text { acetone })(\mathrm{pp})\right]^{2+}$ afforded $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}-\right.$ (pp)] $\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}$ (7-9) (pp = dpq, dppz, dppn), after heating the reaction mixture for 2 h at $75^{\circ} \mathrm{C}$ in $\mathrm{CH}_{3} \mathrm{OH} / \mathrm{CH}_{2} \mathrm{Cl}_{2}$. The dppz complexes $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{L})(\mathrm{dppz})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{1 0})\left(\mathrm{L}=\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}^{-}\right)$and (11) ( $\mathrm{L}=\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}^{-}$) were prepared in an analogous manner by reaction of $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh} \text { (acetone)(dppz) }\right]^{2+}$ with solutions of the respective thiols $\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{SH}$ and $\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{SH}$ in the presence of an equivalent of $30 \% \mathrm{NaOH} / \mathrm{CH}_{3} \mathrm{OH}$. All the complexes were characterised by ${ }^{1} \mathrm{H}$ and ${ }^{13} \mathrm{C}$ NMR and positve-ion LSIMS and gave satisfactory microanalyses. The molecular structures of 2-7 and $\mathbf{1 1}$ were determined by X-ray structural analysis (Table 1).

Complexes 1-3 ( $\mathrm{pp}=\mathrm{en}$, bpy, phen) were synthesised for the purpose of evaluating their in vitro cytotoxicities towards the human cell lines MCF-7 and HT-29. Their cations have been previously characterised in the presence of other counter anions (1, Cl ${ }^{-}$[22]; 2, Cl ${ }^{-}$[23-25], $\mathrm{ClO}_{4}^{-}$[25]; 3, Cl ${ }^{-}$[23-25], $\mathrm{ClO}_{4}^{-}$ [25]) as has that of the dppz complex $5\left(\mathrm{PF}_{6}^{-}\right.$[26]), which itself is known [27]. Crystal structures have been reported for [ $\left(\eta^{5}-\right.$ $\left.\left.\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{bpy})\right]\left(\mathrm{ClO}_{4}\right)$ [20] and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\right.$ phen $\left.)\right]\left(\mathrm{ClO}_{4}\right)$ [25]. The bond lengths and angles in the cations of $\mathbf{2}$ and $\mathbf{3}$ are similar to those determined for the same cations in the presence of perchlorate anions. For instance, complex 3 ( $p p=$ phen) exhibits $\mathrm{Rh}-\mathrm{N}$ distances of 2.100 (2) and 2.121 (2) $\AA$, Rh-C distances in the range 2.141 (3)-2.171 (3) and an $\mathrm{Rh}-\mathrm{Cl}$ bond length of 2.406 (1) $\AA$. The analogous distances in $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\right.$ phen $\left.)\right]\left(\mathrm{ClO}_{4}\right)$ [25] are 2.109 (3) $\AA$ and 2.128 (3), 2.132 (5)-2.165 (4) and 2.386 (1) Å. Similar bond lengths are observed in complexes 4-6, whose cations are depicted in Fig. 1. These exhibit $C_{s}$ crystallographic symmetry in the cases of 4 and 6 . An interesting feature of the half-sandwich cations is the variability of the interplanar angle between their cyclopentadienyl and polypyridyl ring systems. Respective values of $76.6(2)^{\circ}, 58.5(3)^{\circ}$ and $71.6(5)^{\circ}$ are found in complexes 4-6. The significantly larger interplanar angles for $\mathbf{4}$ and $\mathbf{6}$ result from the adoption of a pronounced envelope conformation by the central five-membered NRhNCC chelate ring in these complexes (Fig. 1a and c). A measure of this distortion is given by the respective interplanar angles of $14.7(4)^{\circ}$ in 4 and $9.6(2)^{\circ}$ in $\mathbf{6}$ between the $\mathrm{N} 1-\mathrm{Rh} 1-\mathrm{N} 1 \mathrm{~A}$ and $\mathrm{N} 1-\mathrm{C}-\mathrm{C}-\mathrm{N} 1 \mathrm{~A}$ planes. In contrast,

Table 1
Crystal and refinement data for 2-6, 7 and 11

| Compound | 2 | 3 | 4 | 5 | 6 | $7 \cdot \mathrm{H}_{2} \mathrm{O}$ | 11. $2 \mathrm{H}_{2} \mathrm{O}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $M\left(\mathrm{~g} \mathrm{~mol}^{-1}\right)$ | 578.8 | 602.9 | 654.9 | 705.0 | 755.0 | 918.8 | 864.8 |
| $T$ (K) | 294 | 294 | 113 | 163 | 103 | 294 | 100 |
| Radiation | Mo K $\alpha$ | Mo K $\alpha$ | Mo K $\alpha$ | Mo K $\alpha$ | $\mathrm{Cu} \mathrm{K} \alpha$ | Mo K $\alpha$ | Mo K $\alpha$ |
| Crystal system | Orthorhombic | Triclinic | Monoclinic | Triclinic | Monoclinic | Monoclinic | Monoclinic |
| space group | Pmn2 ${ }_{1}$ | $P(-1)$ | $P 2_{1} / m$ | $P(-1)$ | $P 2_{1} / \mathrm{m}$ | $P 2_{1} / n$ | C2/c |
| $a(\AA)$ | 13.103(2) | 7.963(1) | 7.792(1) | 8.166(2) | 12.198(1) | 8.787(2) | 36.700(9) |
| $b(\AA)$ | 8.461(1) | 11.761(1) | 12.166(1) | 11.848(4) | 12.396(1) | 37.540(8) | 8.787(2) |
| $c(A)$ | 10.647(6) | 13.099(2) | 13.849(1) | 15.698(4) | 12.245(1) | 12.292(3) | 23.019(6) |
| $\alpha\left({ }^{\circ}\right)$ | 90 | 90.12(1) | 90 | 73.42(3) | 90 | 90 | 90 |
| $\beta\left({ }^{\circ}\right)$ | 90 | 99.56(2) | 103.42(1) | 76.09(2) | 110.33(1) | 97.63(3) | 91.28(2) |
| $\gamma\left({ }^{\circ}\right)$ | 90 | 98.26(2) | 90 | 74.11(2) | 90 | 90 | 90 |
| $V\left(\AA^{3}\right)$ | 1180.4(7) | 1196.8(3) | 1277.0(1) | 1378.1(6) | 1736.2(3) | 4018.9(14) | 7422(3) |
| Z | 2 | 2 | 2 | 2 | 2 | 4 | 8 |
| $D\left(\mathrm{~g} \mathrm{~cm}^{-3}\right)$ | 1.629 | 1.673 | 1.703 | 1.699 | 1.444 | 1.518 | 1.548 |
| $F(000)$ | 584 | 608 | 660 | 712 | 764 | 1872 | 3536 |
| $\mu\left(\mathrm{mm}^{-1}\right)$ | 0.974 | 0.964 | 0.913 | 0.853 | 5.713 | 0.659 | 0.638 |
| $2 \theta_{\text {max }}\left({ }^{\circ}\right)$ | 50 | 55 | 55 | 50.5 | 117.9 | 50 | 51.8 |
| Collected reflections | 1561 | 6626 | 8234 | 11544 | 6631 | 8822 | 33444 |
| Independent reflections | 1258 | 5467 | 3002 | 4892 | 2372 | 7081 | 7123 |
| Refined parameters | 160 | 313 | 211 | 384 | 245 | 426 | 500 |
| $R_{1}[I>2 \sigma(I)]$ | 0.048 | 0.032 | 0.047 | 0.045 | 0.056 | 0.122 | 0.054 |
| $w R_{2}$ (all data) ${ }^{\text {a }}$ | 0.130 | 0.082 | 0.110 | 0.091 | 0.157 | 0.323 | 0.134 |
| $S$ (Goodness-of-fit) | 1.117 | 1.042 | 1.058 | 0.648 | 1.057 | 0.957 | 0.845 |
| Maximum/minimum $\Delta p\left(\mathrm{e} \AA^{-3}\right)$ | 1.28/-0.54 | 0.49/-0.45 | 1.51/-0.54 | 0.50/-0.46 | 0.72/-0.65 | 0.97/-0.94 | 1.84/-0.80 |

${ }^{a} w R_{2}=\left[\sum w\left(F_{o}^{2}-F_{c}^{2}\right)^{2} / \sum w\left(F_{o}^{2}\right)^{2}\right]^{1 / 2}$.


the chelate ring in the dppz complex $\mathbf{5}$ is almost flat with an analogous interplanar angle of only $1.7(5)^{\circ}$.

### 2.2. DNA binding studies

### 2.2.1. UV/Vis absorption and melting temperature measurements

Thermal denaturation measurements for calf thymus DNA (CT DNA) in the presence of transition metal complexes such as 1-11 can provide a simple means of gauging the strength of polypyridyl intercalation, provided that electrostatic and hydrogen bonding interactions remain effectively unchanged by pp ligand variation [27-29]. The $\Delta T_{\mathrm{m}}$ values listed in Table 2 were recorded under equilibrium conditions in a 10 mM phosphate buffer at pH 7.2 for $1: 10$ complex/CT DNA mixtures [DNA concentration $=\mathrm{M}$ (nucleotide)] and are indicative of strong DNA intercalation for the cations of the dppz complexes 5 and 8 . Their $\Delta T_{\mathrm{m}}$ values of $+12^{\circ} \mathrm{C}$ are even higher than those of +7 and $+8{ }^{\circ} \mathrm{C}$ recorded for $\left[\left(\eta^{5}-\right.\right.$ $\left.\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}($ HcysOMe $\left.)(\mathrm{dppz})\right]^{2+}($ HcysOMe $=$ cysteine methyl ester $)$ and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\left(\mathrm{H}_{2} \text { metOMe }\right)(\mathrm{dppz})\right]^{3+}\left(\mathrm{H}_{2}\right.$ metOMe $=\mathrm{t}-$ methionine methyl ester), which exhibit strong side-on intercalation with binding constants of, respectively, $2.8 \times 10^{5}$ and $1.3 \times 10^{6} \mathrm{M}^{-1}$ [27]. Relatively high $\Delta T_{\mathrm{m}}$ values in the positive range $6-8^{\circ} \mathrm{C}$ are observed for the dpq complexes $\mathbf{4}$ and $\mathbf{7}$ and the dppn complexes $\mathbf{6}$ and $\mathbf{9}$ and are indicative of possible intercalation or surface stacking of the polypyridyl ligands. Although the higher formal charge ( $n=2$ ) of the kinetically inert $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$-containing dications of 7-9 would be expected to lead to additional stabilization of the DNA helix through stronger electrostatic cation-phosphate interactions, no significant increases are apparent for the $\Delta T_{\mathrm{m}}$ values of these complexes, in comparison to the cations of $4-6$ with the same pp ligand. This finding suggests that rapid aquation [20] of the original monocations of 4-6 will afford dications of the type $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\left(\mathrm{H}_{2} \mathrm{O}\right)(\mathrm{pp})\right]^{2+}$ as equilibrium species for DNA interaction. In striking contrast to the $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ complex 4 , the $\Delta T_{\mathrm{m}}$ value of only $+2{ }^{\circ} \mathrm{C}$ for the analogous ( $\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}$ ) II ${ }^{\text {III }}$ species is clearly in accordance with coordinative Ir-N (nucleobase) binding.

Melting temperatures and UV/Vis-titrations for CT-DNA with the $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Ir}^{\mathrm{III}}$ cations $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Ir}(\mathrm{Hcys} \mathrm{OMe})(\text { phen })\right]^{2+}$ and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Ir}\left(\mathrm{H}_{2} \text { metOMe }\right)(\text { phen })\right]^{3+}$ [27] have demonstrated that the phenanthroline ligand is too small to support intercalation for this class of half-sandwich complexes. The positive $\Delta T_{\mathrm{m}}$ values of $1-2{ }^{\circ} \mathrm{C}$ for these kinetically inert cations are, however, significantly higher than those in the range -5 to $-1^{\circ} \mathrm{C}$ observed for $\mathbf{1 - 3}$, which can potentially bind to the nucleobase N atoms of the biopolymer. A similar $\Delta T_{\mathrm{m}}$ value of $-2^{\circ} \mathrm{C}$ has been reported for $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{H}_{6}\right) \mathrm{RuCl}(\mathrm{en})\right]^{+}$, which preferentially coordinates DNA guanine bases at their endocyclic N7 atoms [11]. ${ }^{1} \mathrm{H}$ NMR studies demonstrated that N7 coordination is complete within 5 min for 1:2 reaction mixtures of $\mathbf{1 - 6}$ with guanosine $5^{\prime}$-monophosphate at

Table 2
Melting temperature shifts $\Delta T_{\mathrm{m}}$, for the interaction of complexes $\left[\left(\eta^{5}\right.\right.$ $\left.\left.\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{L})(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{n}(\mathbf{1 - 1 1})$ with CT DNA at $r=0.1$ in a 10 mM phosphate buffer at pH 7.2 after incubation for 60 min

| Compound | pp | L | $n$ | $\Delta T_{\mathrm{m}}\left({ }^{\circ} \mathrm{C}\right)$ |
| :--- | :--- | :--- | :--- | :--- |
| $\mathbf{1}$ | en | Cl | 1 | -4 |
| $\mathbf{2}$ | bpy | Cl | 1 | -5 |
| $\mathbf{3}$ | phen | Cl | 1 | -1 |
| $\mathbf{4}$ | $d p q$ | Cl | 1 | +6 |
| $\mathbf{5}$ | $d p p z$ | Cl | 1 | +12 |
| $\mathbf{6}$ | $d p p n$ | Cl | 1 | +7 |
| $\mathbf{7}$ | $d p q$ | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | +8 |
| $\mathbf{8}$ | $d p p z$ | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | +12 |
| $\mathbf{9}$ | $d p p n$ | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | +6 |
| $\mathbf{1 0}$ | $d p p z$ | $\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}$ | 1 | +2 |
| $\mathbf{1 1}$ | $d p p z$ | $\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}$ | 1 | +1 |

$30^{\circ} \mathrm{C}$. It can, therefore, be assumed that compounds $\mathbf{1 - 3}$ will rapidly bind to CT DNA through coordinative Rh-N (nucleobase) bonds. The low $\Delta T_{\mathrm{m}}$ values of, respectively, +2 and $+1^{\circ} \mathrm{C}$ for the monocations of the kinetically inert dppz complexes $\mathbf{1 0}$ and $\mathbf{1 1}$ indicate that their aromatic thiolate ligands must impair stable DNA intercalation.

Following incubation periods of $5-30 \mathrm{~min}$, UV/Vis spectra of buffered solutions of complexes $\mathbf{1 - 1 1}(10 \mathrm{mM}$ phosphate buffer, pH 7.2 ) with CT DNA at $25^{\circ} \mathrm{C}$ and $r=0.1$ exhibit no further significant changes, thereby indicating that achievement of equilibrium conditions must be relatively rapid. Pronounced decreases in absorbance for complexes $\mathbf{5}$ and $\mathbf{8}$ at about 364 and 384 nm and shifts of these absorption maxima to higher wavelengths are indicative of dppz intercalation into the DNA double helix. The hypochromic shift $\Delta A / A$ of $-47 \%$ at 364 nm with its associated red shift of 5 nm is depicted for complex 5 in Fig. 2. Similar hypoand bathochromic shifts of respectively $\Delta A / A$ of $-41 \%$ and $\Delta \lambda=3 \mathrm{~nm}$ were also observed for the analogous $\pi-\pi^{*}$ transition of complex 8. The spectral changes observed for the interaction of $\mathbf{5}$ and $\mathbf{8}$ with CT DNA are also similar to those reported for the analogous $\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}^{\text {II }}$ complexes $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{RuCl}(\mathrm{dppz})\right]^{+}$and $\left.\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right)_{2}\right\}(\mathrm{dppz})\right]^{2+}[15]$ and the kinetically inert $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right)$ Ir ${ }^{\text {III }}$ complex $\left.\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \operatorname{Ir}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right)_{2}\right\}(\mathrm{dppz})\right]^{2+}$ [19]. In striking contrast, $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \operatorname{IrCl}(\mathrm{dppz})\right]^{+}$also exhibits initial large negative hypochromic shifts $\Delta A / A$ at 364 and 383 nm after 1 min of mixing with CT DNA, but these are followed by a steady increase in absorbance at both wavelengths. A state of equilibrium is achieved after 10 min , in which the final spectrum exhibits small absorbance increases for the $\pi-\pi^{*}$ transitions in accordance with Ir-N (nucleobase) binding and negligible intercalation or surface stacking.

Kinetic studies have established that the rate constants for substitution of $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ complexes are much higher than for analogous ( $\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}$ )IIIII or ( $\eta^{6}$-arene) Ru'il species [20]. Values of, respectively, $1.59 \times 10^{3} \mathrm{~s}^{-1}, 2.19 \times 10^{2} \mathrm{~s}^{-1}$ and $10.2 \times 10^{-2} \mathrm{~s}^{-1}$ were determined, for instance, for the rate of water exchange at 298 K in $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \operatorname{Rh}(\mathrm{bpy})\left(\mathrm{H}_{2} \mathrm{O}\right)\right]^{2+}$, and its $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right)\right.$ )r ${ }^{\text {III }}$ and $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}^{\text {II }}\right.$ analogues. As a change in the DNA interaction mode from initial intercalation to coordinative M-N (nucleobase) binding should clearly be kinetically favoured for $\mathrm{M}=\mathrm{Rh}^{\text {III }}$ in comparison to $\mathrm{M}=\mathrm{II}{ }^{\mathrm{III}}$, the retention of the former mode for the $\left[\left(\eta^{5}-\right.\right.$ $\left.\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ complexes 5 and $\mathbf{8}$ must result from its relative thermodynamic stability for the 4d transition metal. M-N (nucleobase) bonds will be significantly weaker for rhodium(III) than for its much softer 5d homologue.


Fig. 2. UV/Vis spectra of dppz complex $5(20 \mu \mathrm{M})$ and its equilibrium reaction mixture with CT DNA $(200 \mu \mathrm{M})$ in a 10 mM phosphate buffer ( pH 7.2 ) after 5 min .


Fig. 3. UV/Vis spectra of dppn complex $\mathbf{6}(20 \mu \mathrm{M})$ and its equilibrium mixture with CT DNA $(200 \mu \mathrm{M})$ in a 10 mM phosphate buffer ( pH 7.2 ) after 20 min .

In similarity to the dppz complexes, significant decreases in absorbance are also observed for the dppn complexes 6 (Fig. 3) and 9 at their characteristic maxima at about 323, 398 and 420 nm . Equilibrium is achieved within 12 min for $\mathbf{6}$ and 30 min
for 9 and, in contrast to the analogous $\left[\left(\eta^{5}-C_{5} \mathrm{Me}_{5}\right)\right.$ II ${ }^{\text {III }}$ [19] and $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}^{\text {II }}\right.$ complexes [15], no positive changes in the $\Delta A / A$ values are observed during this time period. The respective final $\Delta A / A$ values for $\mathbf{6}$ and 9 at the first maximum are $-46 \%$ and $-38 \%$. No effective changes in absorption in the range 320450 nm were recorded for complexes $\mathbf{1 - 3}$ ( $\mathrm{pp}=\mathrm{en}$, bpy, phen) on mixing with CT DNA and the changes for complex 4 ( $\mathrm{pp}=\mathrm{dpq}$ ) were of a minor nature. It is interesting to compare the UV/Vis spectra of $1: 10$ mixtures of $\mathbf{1 0}$ and $\mathbf{1 1}$ with CT DNA with those recorded for 5 and $\mathbf{8}$. An intramolecular $\pi-\pi$ interaction between the dppz and naphthalene aromatic systems is apparent for $\mathbf{1 1}$ in the solid state (Fig. 4b), as evidenced by their interplanar angle of only $11.3(3)^{\circ}$. As observed for the dppz complex 5, the five-membered chelating in $\mathbf{1 1}$ is almost flat with an interplanar angle of $1.4(4)^{\circ}$ between $\mathrm{N} 1-\mathrm{Rh}-\mathrm{N} 10$ and $\mathrm{N} 1-\mathrm{C}-\mathrm{C}-\mathrm{N} 10$ planes. The dppz and cyclopentadienyl planes are inclined at $60.7(3)^{\circ}$. Low respective values of $-15 \%$ and $-10 \%$ for $\Delta A / A$ at 364 nm for complex/DNA mixtures of $\mathbf{1 0}$ and $\mathbf{1 1}$ indicate that such interactions are strong enough to prevent a significant degree of intercalation. Fig. 4a depicts the molecular structure of the $\left.\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right)_{2}\right\}(\mathrm{dpq})\right]^{+}$ cation 7, whose dppz and dppn analogues $\mathbf{8}$ and 9 exhibit large negative values of $\Delta A / A$ for $\pi-\pi^{*}$ transitions on mixing with DNA. It is apparent that the steric bulk of tetramethyl thiourea ligand will be greater than that of the benzenethiolate ligand in 10, whose



volume requirements can be estimated from the molecular structure of the analogous $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{dppz})\left(\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}\right)\right]^{+}$cation of $\mathbf{1 1}$ (Fig. 4b). The observation of intercalation for $\mathbf{8}$ but not for $\mathbf{1 0}$ indicates that the intramolecular $\pi-\pi$ interactions may be retained for the latter complex on interaction with CT DNA. In contrast to dpq complex 4, the N1-Rh1-N10 plane in 7 is titled below and not above the plane of the polypyridyl ligand, presumably due to steric repulsion between $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ methyl groups and dpq atoms. This distortion leads to a much smaller interplanar angle of 44.3(5) ${ }^{\circ}$ between the cyclopentadienyl and dpq planes in comparision to that of $76.6(2)^{\circ}$ in 4 . The $\mathrm{N} 1-\mathrm{Rh} 1-\mathrm{N} 10$ plane is inclined at $10.5(9)^{\circ}$ to the N1-Rh1-N10 plane of the chelate ring.

### 2.2.2. Circular dichroismus

Characteristic changes in the observed circular dichroismus (CD) spectra of DNA in the range $220-350 \mathrm{~nm}$ provide a convenient means of monitoring conformational changes for the biopolymer [30,31]. A negative CD band at 246 nm caused by the helical B conformation and a positive band at 275 nm due to base stacking are observed for CT DNA [31]. Addition of the complexes $\mathbf{1 - 3}$ ( $\mathrm{pp}=$ en, bpy, phen) at a $1: 10$ complex/[DNA] molar ratio leads to only minor spectral changes, thereby indicating little distortion of the B helix on formation of $\mathrm{Rh}-\mathrm{N}$ (nucleobase) bonds to the biopolymer. Although aromatic molecules often generate CD bands between 260 and 400 nm on interaction with DNA, the presence of such signals is not necessarily of relevance for the assignment of the binding mode. The observed induced circular dichroismus is caused by the rigid orientation of the molecule with respect to the double helix and this can also result from coordinative, surface or groove binding in addition to intercalation. As depicted in Fig. 5, the complexes 5 and $\mathbf{8}$ do, however, exhibit characteristic negative CD bands with molar ellipticities [ $\theta$ ] of $-3.4 \times 10^{-3}$ and $-4.5 \times$ $10^{-3} \mathrm{deg} \mathrm{cm}^{2} \mathrm{~mol}^{-1}$ at $\lambda=296 \mathrm{~nm}$ and it has previously been established $[15,19,29]$ that the appearance of such bands is, indeed, characteristic for dppz intercalation. The significant increases and the blue shifts of the positive CD bands at 268 nm may of be attributed to resulting changes in the base stacking of the double helix.

In contrast to $\mathbf{5}$ and 8, the dppz complexes 10 and 11 do not exhibit negative induced CD bands at about $\lambda=300 \mathrm{~nm}$. This finding is in accordance with an absence of significant DNA intercalation, as was indicated for these complexes by their low $\Delta T_{\mathrm{m}}$ and


Fig. 5. CD spectra of CT DNA and mixtures of $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{dppz})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{5})$ and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{dppz})\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}(\mathbf{8})$ with CT DNA $(r=0.1)$ in a 10 mM phosphate buffer ( pH 7.2 ) after 2 h incubation.


Fig. 6. CD spectra of CT DNA and mixtures of $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{dpq})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(4)$ and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{dpq})\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}(7)$ with CT DNA in a 10 mM phosphate buffer ( pH 7.2 ) after 2 h incubation.
$-\Delta A / A$ values. When compared to the CD spectrum of CT DNA alone, a broadening and apparent splitting are, however, discernable for the positive bands of the $1: 10$ mixture of the dpq complexes 4 and 7 with the biopolymer (Fig. 6). As 4 and 7 both exhibit absorption maxima for spin-allowed MLCT $\pi-\pi^{*}$ transitions at $\lambda=260$ and 300 nm , it is probable that the shape of the bands in the $270-295 \mathrm{~nm}$ range will be due to spectral overlap with a negative CD contribution caused by intercalating dpq ligands. A similar shape has been observed for the positive band of a mixture of the intercalating complex $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{RuCl}(\mathrm{dpq})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ with CT DNA [15] and this is accompanied by an additional positive band at 315 nm , as is also the case for complexes 4 and 7. The CT DNA bands in the range $220-300 \mathrm{~nm}$ exhibit only minor changes following incubation with the dppn complexes $\mathbf{6}$ and $\mathbf{9}$ for 2 h and remain unchanged over a period of 24 h . Similar observations were also made for the analogous chlorido cations $\left[\left(\eta^{5}-\right.\right.$ $\left.\left.\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{IrCl}(\mathrm{dppn})\right]^{+}$and $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{RuCl}(\mathrm{dppn})\right]^{2+}[19,15]$. In contrast, the interaction with $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \operatorname{Ir}\left\{\left(\mathrm{R}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}(\mathrm{dppn})\right]^{2+}$ ( $\mathrm{R}=\mathrm{H}, \mathrm{Me}$ ) and $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}\left\{\left(\mathrm{H}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}(\mathrm{dppn})\right]^{2+}$ leads to massive changes in the original B DNA conformation. The negative band at about 246 nm disappears in all three cases and the resulting CD spectrum for the ( $\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}$ ) $\mathrm{Ru}^{\text {II }}$ complex is in accordance with DNA damage and complete loss of the B-helix conformation. A large increase in $[\Theta]$ to $10.2 \times 10^{3} \mathrm{deg} \mathrm{cm}{ }^{2} \mathrm{~mol}^{-1}$ for the positive CD bands of the $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \operatorname{Ir}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}(\mathrm{dppn})\right]^{2+} / \mathrm{CT}$ DNA mixture is indicative of the possible adoption of an A DNA conformation.

### 2.2.3. Viscosity measurements

The most convincing evidence for DNA intercalation is provided by viscosity measurements [32,33]. Insertion of aromatics ligands such as dpq or dppz between adjacent nucleobase pairs leads to lengthening and stiffening of the double helix and these changes are reflected in an increase in DNA viscosity. Fig. 7 illustrates the dependence of the logarithmic relative reduced viscosity $\ln \left(\eta / \eta_{0}\right)$ on the concentration function $\ln (1+r)(r=$ [complex]/[DNA]] for the chlorido complexes 4-6. Effective intercalation is confirmed by the slope values of 2.74 and 2.17 for the complexes $4(p p=d p q)$ and 5 ( $\mathrm{pp}=\mathrm{dppz}$ ), in accordance with CD observations. Large increases in $\ln \left(\eta / \eta_{0}\right)$ are also found for the likewise intercalating $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ complexes $7(\mathrm{pp}=\mathrm{dpq})$ and $\mathbf{8}(\mathrm{pp}=\mathrm{dppz})$ with their


Fig. 7. Viscometric titrations of sonicated DNA with the chlorido complexes 4-6 ( $\mathrm{pp}=\mathrm{dpq}, \mathrm{dppz}, \mathrm{dppn}$ ) in a 10 mM phosphate buffer at $\mathrm{pH} 7.2 ; \eta=$ reduced vicosity of the DNA solution in the presence of a complex, $\eta_{0}=$ reduced vicosity of the DNA solution alone, $r=$ [complex]/[DNA].
respective slope values being 2.66 and 1.44. In contrast to the dpq and dppz complexes, significant DNA lengthening is not observed for the dppn complexes 6 and 9 in the $0.0-0.08$ range for $\ln (1+r)$. It can, therefore, be concluded that coordinative Rh-N (nucleobase) binding will probably be predominant for the chlorido complex 6 and electrostatic surface interactions for $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ complex 9 at low values of $r$. Interestingly, a small but steady increase is observed for the relative reduced velocity $\ln \left(\eta / \eta_{0}\right)$ of both complexes at $\ln (1+r)$ values greater than 0.08 . This suggests that surface stacking of adjacent dppn ligands could cause DNA lengthening at higher [complex]/[DNA] ratios. The presence of such interactions is clearly indicated by the significant decreases in absorbance for the $\pi-\pi^{*}$ transitions of complexes $\mathbf{6}$ (Fig. 3) and 9 at $r=0.1$.

The failure of the large dppn ligand to exhibit significant DNA intercalation in its $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\mathrm{III}}$ and $\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}^{\mathrm{II}}$ [15] complexes is in striking contrast to findings for other types of transition metal complexes. For instance, a binding constant $K_{\mathrm{b}}=7.8 \times$ $10^{4} \mathrm{M}^{-1}$ and site size $s$ of 1.4 have been recently determined for the complex $\left[\operatorname{Ir}(\mathrm{dppn})(\mathrm{ppy})_{2}\right]\left(\mathrm{PF}_{6}\right) \quad(\mathrm{Hppy}=2$-phenylpyridine) [34]. This $K_{\mathrm{b}}$ value is significantly larger than that of $2.0 \times$ $10^{4} \mathrm{M}^{-1}$ (site size $s=1.3$ ) obtained for the analogous dppz complex, in agreement with similar measurements for rhenium(I) complexes [35,36] and (tpm)Ru ${ }^{\text {II }}$ complexes of the type [(tpm)$\operatorname{RuCl}(\mathrm{pp})]^{+} \quad$ (tpm = tris(1-pyrazolyl)methane; $\quad \mathrm{pp}=\mathrm{dppn}, \quad \mathrm{dppz}$ ) [37]. These findings are in accordance with the results of Sartorius and Schneider [38] for heterocyclic derivatives with positively charged ammonium groups in their side chains. These authors found that the intercalation binding strength is essentially a function of the size of the aromatic system, independent of the heteroatoms or the presence of local positive charges within the planar moieties. The apparent lack of stable intercalation for complexes $\mathbf{6}$ and 9 and for analogous ( $\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}$ ) Ru ${ }^{\text {II }}$ complexes must, therefore, be attributed to their preferred side-on intercalation mode [27,28]. Close non-bonding contacts to the DNA backbone would be inevitable for the atoms of the additional six-membered ring of dppn and may prevent its suitable side-on alignment between the nucleobases of B DNA. Massive conformational distortions and a possible B to A DNA change are necessary to facilitate dppn intercalation for $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \operatorname{Ir}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}(\mathrm{dppn})\right]^{2+}$ [19]. Small decreases in the reduced viscosity were recorded for mixtures of the complexes $\mathbf{1 - 3}$ with CT DNA at $r$ values in the range 0.080.12 . These decreases may be due to kinking or bending of the double helix $[39,40]$ caused by hydrophobic interactions with the DNA
surface or by intermolecular interactions between coordinating metal fragments.

### 2.3. Cellular uptake

We have previously demonstrated that the cytotoxicity of complexes of the types $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{RuCl}(\mathrm{pp})\right]^{+}$and $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}-\right.$ $\left.\left\{\left(\mathrm{NH}_{2}\right)_{2} \mathrm{CS}\right\}(\mathrm{pp})\right]^{2+}$ is governed by the size of the polypyridyl ligand ( $\mathrm{pp}=\mathrm{dpq}, \mathrm{dppz}, \mathrm{dppn}$ ) and the resulting cellular uptake efficiency [15]. Owing to their decreased lipophilicity, cellular ruthenium levels are much lower for the latter dicationic thiourea complexes than for the monocationic chlorido species and this causes a decrease in cytotoxicity. In order to evaluate the influence of cellular uptake on the cytotoxicity of $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ complexes, we quantified the rhodium concentrations in tumour cells exposed to 1-11 by atomic absorption spectroscopy. The similar $\Delta T_{\mathrm{m}}$ values (Section 2.2.1) for pairs of $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ complexes $\mathbf{4} / \mathbf{7}, \mathbf{5 / 8}$ and $\mathbf{6 / 9}$ with the same polypyridyl ligand indicate that $\mathbf{4 - 6}$ must be present as dications $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\left(\mathrm{H}_{2} \mathrm{O}\right)(\mathrm{pp})\right]^{2+}$ following rapid aquation. As a result of this increase in cation charge, levels of cellular uptake (Table 3) are low for complexes 4-6 (and 1-3) and comparable with the values established for the kinetically inert dicationic complexes 7-9. The small increases in intracellular rhodium levels for the latter complexes (compare the pairs 4/7, 5/8 and 6/9) may be due to the presence of hydrophobic $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ ligands rather than coordinating water molecules. This result is of special interest as the opposite trend was expected based on the fact that 7-9 represent dicationic species, which are supposedly less lipophilic than the monocationic complexes 4-6. A trend to increased uptake efficiency is apparent for both series, in accordance with increasing lipophilicity of the polypyridyl ligands in the order of increasing size dpq < dppz < dppn. However, $100 \mu \mathrm{M}$ concentrations of these complexes are necessary to achieve cellular levels similar to those obtained for $10 \mu \mathrm{M}$ solutions of analogous $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right)$ )IIII and ( $\eta^{6}-$ $\left.\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}^{\text {II }}$ dications. For instance, similar cellular metal levels of respectively $150 \mathrm{ng} \mathrm{Ir} / \mathrm{mg}$ protein ( $=0.78 \mathrm{nmol} \operatorname{Ir} / \mathrm{mg}$ protein) and $85 \mathrm{ng} \mathrm{Ru} / \mathrm{mg}$ protein ( $=0.84 \mathrm{nmol} \mathrm{Ru} / \mathrm{mg}$ protein) were determined

Table 3
Cellular rhodium levels $[\mathrm{ng}(\mathrm{Rh}) / \mathrm{mg}($ protein $)]$ in MCF-7 and HT-29 tumour cells after exposure to given concentrations of complexes $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{L})(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{n}(\mathbf{1}-$ 11) for 4 h

| Compound | pp | L | $n$ | $c(\mu \mathrm{M})$ | MCF-7 | HT-29 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (i) Complexes 1-11 |  |  |  |  |  |  |
| 1 | en | Cl | 1 | 100 | 4.9(2.7) | 4.4(3.2) |
| 2 | bpy | Cl | 1 | 100 | 14.2(9.1) | 10.7(3.1) |
| 3 | phen | Cl | 1 | 100 | 11.9(2.9) | 10.1(1.9) |
| 4 | dpq | Cl | 1 | 100 | 11.3(0.5) | 4.1(1.7) |
| 5 | dppz | Cl | 1 | 100 | 45.0(2.5) | 42.2(4.4) |
| 6 | dppn | Cl | 1 | 10 | 1.8(*) | 3.5(1.2) |
|  |  |  |  | 100 | 189.3(15.5) | 378.1(66.0) |
| 7 | dpq | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | 100 | 18.7(1.7) | 15.2(2.8) |
| 8 | dppz | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | 100 | 90.5(6.1) | 77.7(3.7) |
| 9 | dppn | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | 10 | 5.1(*) | 6.7(0.9) |
|  |  |  |  | 100 | 217.1(12.0) | 331.5(25.2) |
| 10 | dppz | $\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}$ | 1 | 1 | 59.2(2.8) | 20.7(9) |
|  |  |  |  | 10 | 453.3(37.9) | 84.8(20.3) |
|  |  |  |  | 100 | 2337(122.8) | 1137.1(174.7) |
| 11 | dppz | $\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}$ | 1 | 1 | 76.1(29.2) | 17.8(2.2) |
|  |  |  |  | 10 | 398.9(44.2) | 303.7(47.9) |
|  |  |  |  | 100 | 2904(132.3) | 2029(36.5) |
| (ii) Analogous iridium(III) complexes [15,19] |  |  |  |  |  |  |
| 5(Ir) | dppz | Cl | 1 | 10 | n.d. | 70.4(1.0) |
|  |  |  |  | 100 | n.d. | 556.1(32.3) |
| 9(Ir) | dppn | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | 10 | n.d. | 149.6(7.8) |
|  |  |  |  | 100 | n.d. | 906.3(117.6) |

The values in brackets represent the standard errors ( $*$, single value; n.d., not determined).
for HT-29 cells following incubation periods of 4 h with $10 \mu \mathrm{M}$ solutions of $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \operatorname{Ir}\left\{\left(\mathrm{NMe}_{2}\right)_{2} \mathrm{CS}\right\}(\mathrm{dppn})\right]^{2+}$ [41] and $\left[\left(\eta^{6}-\right.\right.$ $\left.\left.\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}\left\{\left(\mathrm{NH}_{2}\right)_{2} \mathrm{CS}\right\}(\mathrm{dppn})\right]^{2+}$ [15]. For the corresponding complexes $\mathbf{6}$ and 9 at $10 \mu \mathrm{M}$ concentrations significantly lower values were found (below $10 \mathrm{ng}(=0.10 \mathrm{nmol}) \mathrm{Rh} / \mathrm{mg}$ protein in all experiments). The low value of $70.4 \mathrm{ng} \mathrm{Ir} / \mathrm{mg}$ protein observed for [ $\left(\eta^{5}-\right.$ $\left.\left.\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{IrCl}(\mathrm{dppn})\right]^{+}$suggests that this complex must also be present as an aqua dication following rapid $\mathrm{H}_{2} \mathrm{O} / \mathrm{Cl}^{-}$exchange. In striking contrast, a cell uptake of $1054.7 \mathrm{ng} \mathrm{Ru} / \mathrm{mg}$ protein was measured for a $10 \mu \mathrm{M}$ solution of the analogous $\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}^{\text {II }}$ complex, for which the aquation rate is much lower.

The influence of cation charge on the level of cellular uptake is clearly apparent for the monocations of $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{L})\right.$ $(\mathrm{dppz})]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right) \mathbf{1 0}\left(\mathrm{L}=\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}^{-}\right)$and $11\left(\mathrm{~L}=\mathrm{C}_{7} \mathrm{H}_{10} \mathrm{~S}^{-}\right)$, where intracellular levels for $1 \mu \mathrm{M}$ solutions are comparable with those established for $100 \mu \mathrm{M}$ solutions of the dppz dications of $\mathbf{5}$ and $\mathbf{8}$. Increased lipophilicity due to the presence of aromatic thiolate ligands may also play a role in improving complex passage through the cell membrane for $\mathbf{1 0}$ and 11.

### 2.4. Cytotoxicity measurements

$\mathrm{IC}_{50}$ values for the complexes 1-11 towards MCF-7 and HT-29 cells are listed in Table 4. As previously reported for analogous ( $\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}$ ) $\mathrm{Ru}^{\text {II }}$ complexes [15], the cytotoxicity of members of the series 4-6 and 7-9 is directly correlated to the surface area of the polypyridyl ligand ( $\mathrm{pp}=\mathrm{dpq}, \mathrm{dppz}, \mathrm{dppn}$ ) and, therefore, to the level of cellular uptake. However the increases in cytotoxicity within the series $\mathrm{dpq}<\mathrm{dppz}<\mathrm{dppn}$ are much less pronounced than for the monocations $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{RuCl}(\mathrm{pp})\right]^{+}$, where, for instance, the $\mathrm{IC}_{50}$ value for HT-29 cells decreases from 30.3 over 2.5 to $0.4 \mu \mathrm{M}[15]$. This weakening of the polypyridyl ligand influence for $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ complexes is most apparent for $\mathrm{pp}=\mathrm{dppn}$ and is clearly a result of the very low levels of cellular uptake for the aqua dications of 4-6 and the $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ dications of $\mathbf{7 - 9}$. It should be noted that we also observed cytotoxic effects for the free polypyridyl ligands, which increase in the order bpy < phen, $\mathrm{dpq}<\mathrm{dppz}<\mathrm{dppn}$ (Table 4). The similarity of the $\mathrm{IC}_{50}$ values for

Table 4
$\mathrm{IC}_{50}$ values $(\mu \mathrm{M})^{\mathrm{a}}$ for the complexes $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{L})(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{n}(\mathbf{1} \mathbf{- 1 1})$

| Compound | pp | L | $n$ | MCF-7 | HT-29 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| (i) Complexes 1-11 |  |  |  |  |  |
| 1 | en | Cl | 1 | >100 | >100 |
| 2 | bpy | Cl | 1 | >100 | >100 |
| 3 | phen | Cl | 1 | 4.7(0.1) | 8.0(1.6) |
| 4 | dpq | Cl | 1 | 5.1(0.2) | 8.5(0.3) |
| 5 | dppz | Cl | 1 | 1.5(0.4) | 4.3(0.2) |
| 6 | dppn | Cl | 1 | 0.8(0.1) | 3.2(0.5) |
| 7 | dpq | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | 5.3(0.7) | 10.7(0.5) |
| 8 | dppz | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | 1.5(0.1) | 4.3(0.1) |
| 9 | dppn | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | 0.91(0.06) | 3.6(0.5) |
| 10 | dppz | $\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}$ | 1 | 0.64(0.08) | $6.1(0.5)$ |
| 11 | dppz | $\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}$ | 1 | 0.56(0.25) | 3.3(0.2) |
| (ii) Polypyridyl ligands |  |  |  |  |  |
|  | bpy |  |  | 52.7(7.8) | 45.7(4.6) |
|  | phen |  |  | 3.5(0.2) | 2.7(0.5) |
|  | dpq |  |  | 6.7(2.0) | 7.0(2.2) |
|  | dppz |  |  | 0.8(0.6) | 1.8(0.2) |
|  | dppn |  |  | 0.15(0.05) | n.d. |
| (iii) Analogous iridium(III) complexes [15,19] |  |  |  |  |  |
| 5(Ir) | dppz | Cl | 1 | 2.3(0.4) | 7.4(0.9) |
| 9(Ir) | dppn | $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ | 2 | 0.17(0.02) | 0.41(0.16) |
| (iv) Cisplatin |  |  | 2.0(0.3) | 7.0(2.0) |  |

[^1]the pp ligands and their $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}{ }^{\text {III }}$ complexes provides strong evidence for the dominant influence of the polypyridyl surface area on the cytotoxic activity of $\mathbf{2 - 1 1}$.

In this context, it is interesting to observe that the $\mathrm{IC}_{50}$ values for half-sandwich dppz complexes all lie within fairly narrow ranges (MCF-7, $1.5-2.5 \mu \mathrm{M}$; HT-29, 2.5-7.4 $\mu \mathrm{M}$ ) independent of the organometallic fragment, the overall cation charge and the nature of the non-polypyridyl ligands. Values of 2.1/2.5 and 2.5/ $6.7 \mu \mathrm{M}$ were reported for MCF-7/HT-29 following incubation with $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{RuCl}(\mathrm{dppz})\right]^{+}$and $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{Ru}\left\{\left(\mathrm{NH}_{2}\right)_{2} \mathrm{CS}\right\}(\mathrm{dppz})\right]^{2+}$, respectively [15]. In contrast to the dppz complexes, significant differences are, however, apparent for both the smaller and larger polypyridyl ligands. Despite their much poorer cell uptake, the dications of the dpq complexes $\mathbf{4}$ and $\mathbf{7}$ are some 2-3 times more active than $\left[\left(\eta^{6}-\mathrm{C}_{6} \mathrm{Me}_{6}\right) \mathrm{RuCl}(\mathrm{dpq})\right]^{+}$, for which $\mathrm{IC}_{50}$ values of 11.1 and $30.5 \mu \mathrm{M}$ were established for MCF-7 and HT-29, respectively. The improvement in cytotoxicity is even more striking for the phen complex 3, which exhibits promising $\mathrm{IC}_{50}$ values of 4.7 and $8.0 \mu \mathrm{M}$ against MCF-7 and HT-29 cells. In contrast, previously tested complexes of the type $\left[\left(\eta^{6} \text {-indan }\right) \mathrm{RuCl}(\mathrm{pp})\right]^{+}$containing phenanthroline derivatives all show poor or no activity towards human A2780 cells (ovarian cancer) [2] and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \operatorname{IrCl}(\text { phen })\right]^{+}$is inactive for MCF-7 and HT-29 cells. As both the en and bpy complexes $\mathbf{1}$ and $\mathbf{2}$ do not exhibit no significant cytotoxicity against these cell lines (Table 4), it can be assumed that cellular interactions involving the phen aromatic system must be responsible for the activity of complex 3.

These observations for phen and dpq complexes indicate that the nature of the organometallic fragment can significantly influence the cytotoxicity of complexes containing smaller polypyridyl ligands. The DNA binding studies and the results of the cellular uptake and cytotoxicity investigations suggest that initial DNA recognition [42] and intercalation rather than kinetically controlled coordinative Rh-N(DNA) binding may be of central importance in determining the biological activity of the polypyridyl complexes 4-11. A case in point is provided by the thiolate complexes $\mathbf{1 0}$ and 11, whose monocations exhibit much better cellular uptake values than those established for the dications of 5 and $\mathbf{8 . 1 0}$ and 11 are indeed, respectively, 2.3 and 2.7 more active towards MCF-7 cells but significant improvements are not observed for HT-29 cells. It seems probable that the impairment of intercalation caused by intramolecular stacking of the dppz ligands with the thiolate aromatic systems, will restrict possible increases in cytotoxicity due to the much higher intracellular concentrations of the complexes. An instructive example for the importance of DNA interactions is given by dppn complex 9 and its ( $\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}$ ) $I \mathrm{r}^{\text {III }}$ counterpart (Tables 3 and 4), whose IC 50 values for MCF-7 and HT29 cells are, respectively, some 5.4 and 8.8 times lower than for the $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ complex. A possible explanation is provided by the fact that the $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Ir}^{\text {III }}$ complex exhibits strong intercalative binding, which leads to a possible B to A change in the DNA conformation [19], whereas only surface stacking is observed for the dppn ligand of the $\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}^{\text {III }}$ analogue. This example also demonstrates that the nature of the metal fragment can in certain cases significantly influence the cytotoxicity of its polypyridyl complexes, even when one of the larger pp ligands (dppz, dppn) is present.

## 3. Conclusions

We have demonstrated that the DNA binding of polypyridyl organorhodium(III) complexes of the types [ $\left.\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{pp})\right]$ $\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right) \mathbf{1 - 6}$ and $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}(\mathrm{pp})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2} \mathbf{7 - 9}$ is governed by the size of the polypyridyl ligand. Whereas stable intercalative binding is observed for the dpq complexes 4 and 7 and the dppz complexes 5 and $\mathbf{8}$, the surface area of the dppn
ligand of $\mathbf{6}$ and $\mathbf{9}$ is apparently too large to support stable side-on intercalation. Intramolecular interactions between the aromatic systems of the thiolate $\mathrm{L}^{-}$and dppz ligands appear to prevent significant DNA intercalation for $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{L})-\right.$ (pp) $]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right), \mathbf{1 0}\left(\mathrm{L}=\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}^{-}\right)$and $\mathbf{1 1}\left(\mathrm{L}=\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}^{-}\right)$.

Rapid $\mathrm{Cl}^{-} / \mathrm{H}_{2} \mathrm{O}$ exchange leads to formation of aqua dications for complexes 1-6 and similar low levels of cellular uptake are observed for $4-6$ and their kinetically inert $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}$ analogues $\mathbf{7 - 9}$. The cytotoxicity of the latter compounds $4-9$ is governed by the size of the polypyridyl ligands with $\mathrm{IC}_{50}$ values varying in the order dppn < dppz < dpq. An exception to this rule is provided by the phen complex 3, whose $\mathrm{IC}_{50}$ values of 4.7 and $8.0 \mu \mathrm{M}$ against MCF-7 and HT-29 cells are comparable with those observed for the dpq complexes 4 and 7.

## 4. Experimental

Solvents were dried and distilled before use. ${ }^{1} \mathrm{H}$ and ${ }^{13} \mathrm{C}$ NMR spectra were recorded on a Bruker DRX 400 spectrometer and LSIMS data (liquid secondary ion mass spectrometry) on a VG Autospec instrument using 3-nitrobenzyl alcohol as the matrix. ${ }^{13} \mathrm{C}$ NMR signals for the $\mathrm{CF}_{3} \mathrm{SO}_{3}{ }^{-}$anions of $\mathbf{1 - 1 1}$ were observed in the $\delta$ range $121.8-122.8 \mathrm{ppm}$ and are not listed for individual complexes. An analytik jena SPECORD 200 was employed for UV-Vis measurements and CD spectra were registered on a Jasco J-715 instrument in the range $220-400 \mathrm{~nm}$ for $1: 10$ complex/[DNA] mixtures [DNA concentrations in M (nucleotide)] in a 10 mM phosphate buffer at pH 7.2 . Elemental analysis were performed on a Vario El (Elementar Analysensysteme). $\mathrm{RhCl}_{3} \cdot 3 \mathrm{H}_{2} \mathrm{O}$ and $\mathrm{Ag}\left(\mathrm{CF}_{3}\right.$ $\mathrm{SO}_{3}$ ) were obtained from Chempur, 2,2'-bipyridine (bpy), 1,10-phenanthroline (phen), and tetramethyl thiourea from Acros, ethylenediamine (en) from Riedel de Haen and 1-benzenethiol and 2-naphthalenethiol from TCI. Solvents were purchased from TJ Baker and DEUTERO GmbH and NaOMe from Merck. The starting complex $\left[\left\{\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}\right\}_{2}(\mu-\mathrm{Cl})_{2}\right]$ [43] and the polypyridyl ligands dpq [44], dppz [45] and dppn [34] and [( $\eta^{5}-$ $\left.\left.\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{dppz})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ (5) [27] were synthesised according to literature procedures.

### 4.1. Preparation of 1-4 and 6-11

### 4.1.1. $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{en})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{1})$

Two equivalents of $\mathrm{Ag}\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(51.4 \mathrm{mg}, 0.2 \mathrm{mmol})$ were added to $\left[\left\{\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}\right\}_{2}(\mu-\mathrm{Cl})_{2}\right](61.8 \mathrm{mg}, 0.1 \mathrm{mmol})$ in 10 ml acetone and stirred in the dark for 0.5 h . Filtration of the resulting AgCl precipitate and subsequent solvent removal under vacuum afforded $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\text { acetone })_{2}\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$, which was stirred with the ligand ethylenediamine (en) ( $13.5 \mu \mathrm{l}, 0.2 \mathrm{mmol}$ ) in $\mathrm{CH}_{3} \mathrm{OH} / \mathrm{CH}_{2} \mathrm{Cl}_{2}$ $(1: 1,10 \mathrm{ml})$ at $75^{\circ} \mathrm{C}$ for 2 h . Following cooling and solvent removal under vacuum, the resulting solid was dissolved in $3 \mathrm{ml} \mathrm{CH}_{3} \mathrm{OH}$. The product was subsequently precipitated by addition of diethyl ether, washed and dried in vacuo. Yield: $71 \%(68 \mathrm{mg}) . \mathrm{C}_{13} \mathrm{H}_{23^{-}}$ $\mathrm{ClF}_{3} \mathrm{~N}_{2} \mathrm{O}_{3} \mathrm{RhS}$; $M=482.7 \mathrm{~g} / \mathrm{mol}$. Anal. Calc.: C, 32.3; H, 4.8; N, 5.8; S, 6.7. Found: C, 32.0; H, 4.8; N, 5.9; S, 6.7\%. LSIMS: m/z 447 (65\%) $\quad[\mathrm{M}-\mathrm{Cl}]^{+}, 333$ (100\%) $\quad\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, \quad 297 \quad$ (35\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\mathrm{Cl}\right]^{+} .{ }^{1} \mathrm{H}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.68$ (s, $15 \mathrm{H}, \mathrm{Cp}^{*}-$ $\left.\mathrm{CH}_{3}\right), 2.33\left(\mathrm{~mm}, 2 \mathrm{H}\right.$, en- $\mathrm{CH}_{2}$ ), 2.53 ( $\mathrm{m}, 2 \mathrm{H}$, en- $\mathrm{CH}_{2}$ ), $4.31(\mathrm{~m}, 2 \mathrm{H}$, en- $\mathrm{NH}_{2}$ ), $5.02\left(\mathrm{~m}, 2 \mathrm{H}\right.$, en- $\left.\mathrm{NH}_{2}\right) \mathrm{ppm} .{ }^{13} \mathrm{C}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=8.4\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 44.2\left(\mathrm{en}-\mathrm{CH}_{2}\right), 93.6\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right) \mathrm{ppm}$.

### 4.1.2. $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}\left(2,2^{\prime}-\right.\right.$ bpy $\left.)\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{2})$

Preparation as for 1 with the ligand bpy ( $31.3 \mathrm{mg}, 0.2 \mathrm{mmol}$ ). Yield: $76 \%(87 \mathrm{mg}) . \mathrm{C}_{21} \mathrm{H}_{23} \mathrm{ClF}_{3} \mathrm{~N}_{2} \mathrm{O}_{3} \mathrm{RhS} ; M=578.8 \mathrm{~g} / \mathrm{mol}$; Anal. Calc.: C, 43.6; H, 4.0; N, 4.8; S, 5.5. Found: C, 43.5; H, 4.0; N, 4.8; S, 5.4\%. LSIMS: $m / z 580$ (6\%) $[\mathrm{M}]^{+}, 543$ (36\%) $[\mathrm{M}-\mathrm{Cl}]^{+}, 429$ (100\%)
$\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, 393(45 \%)\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\mathrm{Cl}\right]^{+} .{ }^{1} \mathrm{H}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.67\left(\mathrm{~s}, 15 \mathrm{H}, \mathrm{Cp}^{*}-\mathrm{CH}_{3}\right.$ ), 7.87 (dd, $2 \mathrm{H}, \mathrm{H} 4 / \mathrm{H} 4{ }^{\prime}$ ), 8.33 (dd, 2H, H5/H5'), 8.68 (d, 2H, H6/H6'), 8.97 (d, 2H, H3/H3') ppm. ${ }^{13} \mathrm{C}$ NMR ( $d_{6}$-DMSO, $\left.30^{\circ} \mathrm{C}\right): \delta=8.4\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 96.8\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 123.7$, 128.3, 140.3, 152.2 (bpy-CH), 153.9 (bpy-C) ppm.

### 4.1.3. $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(1,10-\mathrm{phen})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ (3)

Preparation as for $\mathbf{1}$ with the ligand phen ( $36 \mathrm{mg}, 0.2 \mathrm{mmol}$ ). Yield: $85 \%(103 \mathrm{mg}) . \mathrm{C}_{23} \mathrm{H}_{23} \mathrm{ClF}_{3} \mathrm{~N}_{2} \mathrm{O}_{3} \mathrm{RhS} ; M=602.9 \mathrm{~g} / \mathrm{mol}$. Anal. Calc.: C, 45.8; H, 3.8; N, 4.6; S, 5.3. Found: C, 45.3; H, 3.8; N, 4.6; S, 5.6\%. LSIMS: $m / z 604$ (10\%) [M] ${ }^{+}, 567$ ( $70 \%$ ) [M-Cl] ${ }^{+} .453$ (100\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, 417$ (42\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\mathrm{Cl}\right]^{+} .{ }^{1} \mathrm{H}$ NMR $\left(d_{6}-\right.$ DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.74$ (s, $15 \mathrm{H}, \mathrm{Cp}^{*}-\mathrm{CH}_{3}$ ), 8.20 (dd, $2 \mathrm{H}, \mathrm{H} 3 / \mathrm{H} 8$ ), 8.33 (s, 2H, H5/H6), 8.95 (d, 2H, H4/H7), 9.39 (d, 2H, H2/H9) ppm. ${ }^{13} \mathrm{C}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=8.5\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right)$, $96.9\left(\mathrm{Cp}^{*}-\right.$ $\mathrm{CCH}_{3}$ ), 127.0, 127.6, 139.0, 152.4 (phen-CH), 130.0, 144.7(phen-C) ppm.

### 4.1.4. $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{dpq})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$ (4)

Preparation as for $\mathbf{1}$ with the ligand dpq ( $46.5 \mathrm{mg}, 0.2 \mathrm{mmol}$ ). Yield: $83 \%(108 \mathrm{mg}) . \mathrm{C}_{25} \mathrm{H}_{23} \mathrm{ClF}_{3} \mathrm{~N}_{4} \mathrm{O}_{3} \mathrm{RhS} ; ~ M=654.9 \mathrm{~g} / \mathrm{mol}$; Anal. Calc.: C, 45.8; H, 3.5; N, 8.6; S, 4.9. Found: C, 45.8; H, 3.5; N, 8.6; S, 4.9\%. LSIMS: m/z 505 (100\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, 469$ ( $60 \%$ ) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\mathrm{Cl}\right]^{+} .{ }^{1} \mathrm{H}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.77$ ( $\mathrm{s}, 15 \mathrm{H}, \mathrm{Cp}{ }^{*}-$ $\mathrm{CH}_{3}$ ), 8.38 (dd, 2H, H3/H8), 9.35 (s, 2H, H11/H12), 9.51 (d, 2H, H4/H7), 9.72 (d, 2H, H2/H9) ppm. ${ }^{13} \mathrm{C}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=8.5\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 97.0\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 128.1,128.7,135.4,153.7$ (dpq-CH), 138.8, 146.3, 146.8 (dpq-C) ppm.

### 4.1.5. $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\right.$ dppn $\left.)\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\boldsymbol{6})$

Preparation as for $\mathbf{1}$ with the ligand dppn ( $66.5 \mathrm{mg}, 0.2 \mathrm{mmol}$ ). Yield: $68 \%(107 \mathrm{mg}) . \mathrm{C}_{33} \mathrm{H}_{27} \mathrm{ClF}_{3} \mathrm{~N}_{4} \mathrm{O}_{3} \mathrm{RhS} \cdot 2 \mathrm{H}_{2} \mathrm{O} ; M=791.0 \mathrm{~g} / \mathrm{mol}$; Anal. Calc.: C, 50.1 ; H, 3.9; N, 7.1; S, 4.0. Found: C, 50.0 ; H, 3.9; $\mathrm{N}, 7.0 ; \mathrm{S}, 4.2 \%$. LSIMS: $m / z 605$ ( $100 \%$ ) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, 569$ (75\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\mathrm{Cl}\right]^{+} .{ }^{1} \mathrm{H}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.77$ ( $\mathrm{s}, 15 \mathrm{H}, \mathrm{Cp}{ }^{*}-$ $\mathrm{CH}_{3}$ ), 7.74 (dd, 2H, H13/H14), 8.42 (dd, 2H, H3/H8), 8.47 (dd, 2H, H12/H15), 9.18 (s, 2H, H11/H16), 9.44 (dd, 2H, H4/H7), 9.75 (dd, $2 \mathrm{H}, \mathrm{H} 2 / \mathrm{H} 9) \mathrm{ppm} .{ }^{13} \mathrm{C}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=8.5\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right)$, $97.1\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 127.9,128.5,128.6,129.8,129.9,135.7$ (dppnCH), 134.5, 137.9, 140.4, 148.3, 153.9 (dppn-C) ppm.

### 4.1.6. $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{dpq})\left\{\mathrm{SC}\left(\mathrm{NMe}_{2}\right)_{2}\right\}\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}(7)$

Two equivalents of $\mathrm{Ag}\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(51.4 \mathrm{mg}, 0.2 \mathrm{mmol})$ were added to $\left[\left\{\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}\right\}_{2}(\mu-\mathrm{Cl})_{2}\right](61.8 \mathrm{mg}, 0.1 \mathrm{mmol})$ in 10 ml acetone and stirred in the dark for 0.5 h . Filtration of the resulting AgCl precipitate and subsequent solvent removal under vacuum yielded $\left.\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl} \text { (acetone }\right)_{2}\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)$, which was stirred with the ligand dpq ( $46.5 \mathrm{mg}, 0.2 \mathrm{mmol}$ ) in $\mathrm{CH}_{3} \mathrm{OH} / \mathrm{CH}_{2} \mathrm{Cl}_{2}(1: 1,10 \mathrm{ml})$ at $75^{\circ} \mathrm{C}$ for 2 h . Following cooling and solvent removal under vacuum, the red product $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{RhCl}(\mathrm{dpq})\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(4)$ was dissolved in 10 ml acetone and stirred in the dark for 0.5 h with $\mathrm{Ag}\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(51.4 \mathrm{mg}, 0.2 \mathrm{mmol})$. After filtration of the resulting AgCl precipitate and solvent removal red $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}\right.$ (acetone $)(\mathrm{dpq})]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}$ was stirred with $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}(26.5 \mathrm{mg}$, $0.2 \mathrm{mmol})$ for 2 h in $\mathrm{CH}_{3} \mathrm{OH} / \mathrm{CH}_{2} \mathrm{Cl}_{2}(1: 1,10 \mathrm{ml})$ at $75^{\circ} \mathrm{C}$. Following cooling and solvent removal the remaining solid was dissolved in 3 ml CH 33 OH and then slowly precipitated by covering the solution with diethyl ether. The resulting final product was dried in vacuo. Yield: $71 \%(133 \mathrm{mg}) . \mathrm{C}_{31} \mathrm{H}_{35} \mathrm{~F}_{6} \mathrm{~N}_{6} \mathrm{O}_{6} \mathrm{RhS}_{3} \cdot 2 \mathrm{H}_{2} \mathrm{O} ; M=936.8 \mathrm{~g} / \mathrm{mol}$; Anal. Calc.: C, 39.7; H, 4.2; N, 9.0; S, 10.3. Found: C, 39.5; H, 4.2; $\mathrm{N}, 9.0 ; \mathrm{S}, 10.3 \%$. LSIMS: m/z 751 (22\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, 619$ (44\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}\right]^{+}, 470$ (100\%) $\quad\left[\mathrm{M}-2 \mathrm{CF}_{3} \mathrm{SO}_{3}-\right.$ $\left.\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}\right]^{+} .{ }^{1} \mathrm{H}$ NMR $\left(d_{6}\right.$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.73$ (s, $15 \mathrm{H}, \mathrm{Cp}{ }^{*}-$ $\left.\mathrm{CH}_{3}\right), 2.31\left(\mathrm{~s}, 12 \mathrm{H}, \mathrm{CH}_{3}-\mathrm{SC}\left\{\mathrm{N}\left(\mathrm{CH}_{3}\right)_{2}\right\}_{2}\right), 8.41$ (dd, $2 \mathrm{H}, \mathrm{H} 3 / \mathrm{H} 8$ ), 9.40 (s, 2H, H11/H12), 9.47 (d, 2H, H4/H7), 9.77 (d, 2H, H2/H9) ppm. ${ }^{13} \mathrm{C}$ NMR ( $d_{6}$-DMSO, $\left.30^{\circ} \mathrm{C}\right): \delta=8.3\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 42.7\left(\mathrm{SC}\left\{\mathrm{N}\left(\mathrm{CH}_{3}\right)_{2}\right\}_{2}\right)$,
$99.4\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 128.5,129.2,136.0,154.4$ (dpq-CH), 138.9, 146.0, 147.0 (dpq-C), $179.4\left(\mathrm{SC}\left\{\mathrm{N}\left(\mathrm{CH}_{3}\right)_{2}\right\}_{2}\right) \mathrm{ppm}$.

### 4.1.7. $\left[\left(\eta^{5}-C_{5} \mathrm{Me}_{5}\right) R h(d p p z)\left\{S C\left(\mathrm{NMe}_{2}\right)_{2}\right\}\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}(\boldsymbol{8})$

Preparation as for $\mathbf{7}$ with the ligands dppz ( $56.5 \mathrm{mg}, 0.2 \mathrm{mmol}$ ) and $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS} \quad(26.5 \mathrm{mg}, \quad 0.2 \mathrm{mmol})$. Yield: $77 \% ~(152 \mathrm{mg})$. $\mathrm{C}_{35} \mathrm{H}_{37} \mathrm{~F}_{6} \mathrm{~N}_{6} \mathrm{O}_{6} \mathrm{RhS}_{3} \cdot 2 \mathrm{H}_{2} \mathrm{O} ; M=986.8 \mathrm{~g} / \mathrm{mol}$; Anal. Calc.: C, 42.6; H, 4.2; N, 8.5; S, 9.8. Found: C, 42.5; H, 4.3; N, 8.4; S, 10.7\%. LSIMS: $\mathrm{m} / \mathrm{z} 801(43 \%)\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, 669(38 \%)\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}\right]^{+}$, 520 ( $100 \%$ ) $\left[\mathrm{M}-2 \mathrm{CF}_{3} \mathrm{SO}_{3}-\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}\right]^{+} .{ }^{1} \mathrm{H}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.75\left(\mathrm{~s}, 15 \mathrm{H}, \mathrm{Cp}^{*}-\mathrm{CH}_{3}\right), 2.35\left(\mathrm{~s}, 12 \mathrm{H}, \mathrm{CH}_{3}-\mathrm{SC}\left\{\mathrm{N}\left(\mathrm{CH}_{3}\right)_{2}\right\}_{2}\right)$, 8.22 (d, 2H, H12/H13), 8.42 (dd, 2H, H3/H8), 8.54 (dd, 2H, H11/ H14), 9.46 (d, 2H, H4/H7), 9.87 (dd, $2 \mathrm{H}, \mathrm{H} 2 / \mathrm{H} 9$ ) ppm. ${ }^{13} \mathrm{C}$ NMR $\left(d_{6}\right.$-DMSO, $\left.30^{\circ} \mathrm{C}\right): \delta=8.3\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 42.7\left(\mathrm{SC}\left(\mathrm{N}\left(\mathrm{CH}_{3}\right)_{2}\right\}_{2}\right), 99.5$ $\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 128.8,129.4,129.8,139.5,154.5$ (dppz-CH), 132.8, 136.3, 142.1, 147.2 (dppz-C), $179.2\left(\mathrm{SC}\left\{\mathrm{N}\left(\mathrm{CH}_{3}\right)_{2}\right\}_{2}\right) \mathrm{ppm}$.

### 4.1.8. $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me} e_{5}\right) \mathrm{Rh}(\mathrm{dppn})\left\{\mathrm{SC}\left(\mathrm{NMe}_{2}\right)_{2}\right\}\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)_{2}$ (9)

Preparation as for 7 with the ligands dppn ( $66.5 \mathrm{mg}, 0.2 \mathrm{mmol}$ ) and $\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}(26.5 \mathrm{mg}, 0.2 \mathrm{mmol})$. Yield: $66 \%(139 \mathrm{mg}) . \mathrm{C}_{39} \mathrm{H}_{39}-$ $\mathrm{F}_{6} \mathrm{~N}_{6} \mathrm{O}_{6} \mathrm{RhS}_{3} \cdot 3 \mathrm{H}_{2} \mathrm{O} ; M=1054.9 \mathrm{~g} / \mathrm{mol}$; Anal. Calc.: C, $44.4 ; \mathrm{H}, 4.3$; N, 8.0; S, 9.1. Found: C, 44.9; H, 4.3; N, 8.0; S, 10.4\%. LSIMS: m/z 851 (47\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, 719$ (48\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}\right]^{+}$, 570 (100\%) [ $\left.\mathrm{M}-2 \mathrm{CF}_{3} \mathrm{SO}_{3}\left\{\left(\mathrm{Me}_{2} \mathrm{~N}\right)_{2} \mathrm{CS}\right\}\right]^{+},{ }^{1} \mathrm{H} \quad \mathrm{NMR} \quad\left(d_{6}\right.$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.74\left(\mathrm{~s}, 15 \mathrm{H}, \mathrm{Cp}^{*}-\mathrm{CH}_{3}\right), 2.41\left(\mathrm{~s}, 12 \mathrm{H}, \mathrm{CH}_{3}-\mathrm{SC}\left(\mathrm{N}\left(\mathrm{CH}_{3}\right)_{2}\right\}_{2}\right)$, 7.80 (dd, 2H, H13/H14), 8.42 (dd, 2H, H3/H8), 9.27 (s, 2H, H11/ H16), 9.43 (dd, 2H, H4/H7), 9.49 (m, 2H, H12/H15), 9.85 (dd, 2H, H2/H9) ppm.

### 4.1.9. $\left[\left(\eta^{5}-C p^{*}\right) R h(d p p z)\left(C_{6} H_{5} S\right)\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right)(\mathbf{1 0})$

Preparation as for $\mathbf{7}$ with the ligands dppz ( $56.5 \mathrm{mg}, 0.2 \mathrm{mmol}$ ) and $\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{SH}(20.5 \mu \mathrm{l}, 0.2 \mathrm{mmol})$ and additional $37 \mu \mathrm{l} 30 \% \mathrm{NaOH} /$ $\mathrm{CH}_{3} \mathrm{OH}(0.2 \mathrm{mmol})$. Yield: $86 \%(140 \mathrm{mg}) . \mathrm{C}_{35} \mathrm{H}_{30} \mathrm{~F}_{3} \mathrm{~N}_{4} \mathrm{O}_{3} \mathrm{RhS}_{2} \cdot 2 \mathrm{H}_{2} \mathrm{O}$; $M=814.7 \mathrm{~g} / \mathrm{mol}$; Anal. Calc.: C, 51.6 ; H, 4.2; N, 6.9; S, 7.9. Found: C, 51.2; H, 4.2; N, 6.7; S, 8.0\%. LSIMS: m/z 629 (82\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}, 519$ (100\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\left\{\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}\right\}\right]^{+},{ }^{1} \mathrm{H}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.78$ ( $\mathrm{s}, 15 \mathrm{H}, \mathrm{Cp}^{*}-\mathrm{CH}_{3}$ ), 5.83 (d, 2H, $\left.\mathrm{H}^{\prime} / \mathrm{H6}^{\prime}\right), 5.90\left(\mathrm{t}, 2 \mathrm{H}, \mathrm{H}^{\prime} / \mathrm{H}^{\prime}\right), 5.99$ (t, 1H, H4'), 8.16 (d, 2H, H12/H13), 8.26 (dd, 2H, H3/H8), 8.47 (d, $2 \mathrm{H}, \mathrm{H} 11 / \mathrm{H} 14$ ), 9.27 (d, 2H, H4/H7), 9.57 (d, 2H, H2/H9) ppm. ${ }^{13} \mathrm{C}$ NMR ( $d_{6}$-DMSO, $\left.30^{\circ} \mathrm{C}\right)$ : $\delta=8.0\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 97.0\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right)$, 129.4, 132.5, 134.2, 139.1153 .6 (dppz-CH), 134.4, 138.0, 141.8, 146.5 (dppz-C), 126.27, 126,32, 127. 70, 127.87, 128.95 (CH $\left.\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}\right), 123.92\left(\mathrm{C}-\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{~S}\right) \mathrm{ppm}$.

### 4.1.10. $\left[\left(\eta^{5}-\mathrm{C}_{5} \mathrm{Me}_{5}\right) \mathrm{Rh}(\mathrm{dppz})\left(\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}\right)\right]\left(\mathrm{CF}_{3} \mathrm{SO}_{3}\right) \cdot \mathrm{H}_{2} \mathrm{O}$ (11)

Preparation as for $\mathbf{7}$ with the ligands dppz ( $56.5 \mathrm{mg}, 0.2 \mathrm{mmol}$ ) and $\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{SH}(32 \mathrm{mg}, 0.2 \mathrm{mmol}$ ) and additional $37 \mu \mathrm{l} 30 \% \mathrm{NaOH} /$ $\mathrm{CH}_{3} \mathrm{OH}(0.2 \mathrm{mmol})$. Yield: $67 \%(113 \mathrm{mg}) . \mathrm{C}_{39} \mathrm{H}_{32} \mathrm{~F}_{3} \mathrm{~N}_{4} \mathrm{O}_{3} \mathrm{RhS}_{2} \cdot \mathrm{H}_{2} \mathrm{O}$; $M=846.7 \mathrm{~g} / \mathrm{mol}$; Anal. Calc.: C, 55.3 ; H, 4.1; N, 6.6; S, 7.6. Found: C, 55.7; H, 4.0; N, 6.6; S, 7.3. LSIMS: $\mathrm{m} / \mathrm{z} 679$ (90\%) $\left[\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}\right]^{+}$, 520 (100\%) [ $\left.\mathrm{M}-\mathrm{CF}_{3} \mathrm{SO}_{3}-\left\{\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}\right\}\right]^{+},{ }^{1} \mathrm{H}$ NMR ( $d_{6}$-DMSO, $30^{\circ} \mathrm{C}$ ): $\delta=1.81\left(\mathrm{~s}, 15 \mathrm{H}, \mathrm{Cp}^{*}-\mathrm{CH}_{3}\right), 5.81(\mathrm{~s}, 1 \mathrm{H}), 6.08(\mathrm{~d}, 1 \mathrm{H}), 6.21(\mathrm{~m}, 1 \mathrm{H})$, $6.50(\mathrm{~m}, 3 \mathrm{H}), 6.73(\mathrm{~d}, 1 \mathrm{H}), 8.11(\mathrm{~d}, 2 \mathrm{H}, \mathrm{H} 12 / \mathrm{H} 13), 8.23(\mathrm{dd}, 2 \mathrm{H}$, H3/H8), 8.32 (d, 2H, H11/H14), 9.29 (d, 2H, H4/H7), 9.39 (d, 2H, H2/H9) ppm. ${ }^{13} \mathrm{C}$ NMR ( $d_{6}$-DMSO, $30{ }^{\circ} \mathrm{C}$ ): $\delta=8.1\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 97.2$ $\left(\mathrm{Cp}^{*}-\mathrm{CCH}_{3}\right), 129.5,131.0,132.2,141.5,153.6$ (dppz-CH), 134.2, 135.6, 138.4, 146.1 (dppz-C), 121.1, 123.3, 123.9, 124.5, 125.2, 125.7, $127.4\left(\mathbf{C H}-\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}\right), 125.9,128.7,129.1\left(\mathrm{C}_{\left.-\mathrm{C}_{10} \mathrm{H}_{7} \mathrm{~S}\right)}\right) \mathrm{ppm}$.

### 4.2. X-ray structural analyses

Crystals of compounds 2-7 and $\mathbf{1 1}$ suitable for X-ray structural analysis were obtained by slow evaporation of $\mathrm{CH}_{3} \mathrm{OH} / \mathrm{H}_{2} \mathrm{O}$ solutions. Their crystal and refinement data are summarised in Table 1. Intensity data for $\mathbf{2 , 3}$ and $\mathbf{7} \cdot \mathrm{H}_{2} \mathrm{O}$ were collected on a Siemens P4 diffractometer at 294 K using $\omega$ scans and Mo $\mathrm{K} \alpha$ radiation
( $\lambda=0.71073 \AA$ ) . An Oxford Diffraction Sapphire2 CCD diffractometer was employed for the intensity data collection of compounds 4-6 and $11 \cdot 2 \mathrm{H}_{2} \mathrm{O}$ using $1^{\circ} \omega$ scans and Mo $\mathrm{K} \alpha$ (for 4, 5 and $11 \cdot 2 \mathrm{H}_{2} \mathrm{O}$ ) or $\mathrm{Cu} \mathrm{K} \alpha$ radiation (for $\mathbf{6}=1.54178 \AA$ ). Semi-empirical absorption corrections were applied to the intensities in all cases. The structures were solved by direct methods with shelxs and refined against $F^{2}$ with shelxl [46]. Anisotropic temperature factors were introduced for non-hydrogen atoms and with exception of water molecules, protons were refined at geometrically calculated positions as riding atoms. The high values of $R_{1}(0.122)$ and $w R_{2}$ (0.323) for $7 \cdot \mathrm{H}_{2} \mathrm{O}$ are due to disorder of the $\mathrm{CF}_{3} \mathrm{SO}_{3}^{-}$counter ions.

### 4.3. DNA binding studies

The thermal denaturation temperatures $T_{\mathrm{m}}$ of $1: 10$ complex/ DNA mixtures [DNA concentration $=\mathrm{M}$ (nucleotide)] were determined for $\mathbf{1 - 1 1}$ in a 10 mM phosphate buffer at pH 7.2 . Measurements for $\mathbf{1 0}$ and $\mathbf{1 1}$ were performed in the presence of $1 \%$ DMSO. Melting curves were recorded at $1^{\circ}$ steps for the wavelength $\lambda=260 \mathrm{~nm}$ with an analytikjena SPECORD 200 spectrometer equipped with a Peltier temperature controller. $T_{\mathrm{m}}$ values were calculated by determining the midpoints of melting curves from the first order derivatives. The experimental $\Delta T_{\mathrm{m}}$ values are estimated to be accurate within $\pm 1^{\circ} \mathrm{C}$. Concentrations of CT DNA were determined spectrophotometrically using the molar extinction coefficient $\varepsilon_{260}=6600 \mathrm{M}^{-1} \mathrm{~cm}^{-1}$ [47].

Viscosities for mixtures of complexes 1-9 with sonicated DNA were determined using a Cannon-Ubbelhode semi-micro dilution viscometer (Series No. 75, Cannon Instruments Co.) held at a constant temperature of $25^{\circ} \mathrm{C}$ in a water bath. The viscometer initially contained 2 ml of 0.4 mM sonicated DNA solution in a 10 mM phosphate buffer ( pH 7.2 ). 0.2 mM complex solutions also containing 0.4 mM sonicated DNA were added in increments of $100 \mu \mathrm{l}$ from a micropipet. Solutions were passed through filters to remove particulate material prior to use. Reduced viscosities $\eta$ were calculated by literature methods [32] and plotted as $\operatorname{In}\left(\eta / \eta_{\mathrm{o}}\right)\left(\eta_{\mathrm{o}}=\right.$ reduced viscosity of the DNA solution in the absence of complex) against $\operatorname{In}(1+r)$ for rod-like DNA (approximately 600 base pairs).

### 4.4. Cell cultures

MCF-7 breast cancer and HT-29 human colon carcinoma cells were maintained in $10 \%(\mathrm{v} / \mathrm{v})$ fetal calf serum containing cell culture medium (minimum essential medium eagle supplemented with $2.2 \mathrm{~g} \mathrm{NaHCO} 3,110 \mathrm{mgl}^{-1}$ sodium pyruvate and $50 \mathrm{mg} \mathrm{l}^{-1}$ gentamicin sulfate adjusted to pH 7.4 ) at $37^{\circ} \mathrm{C}: 5 \% \mathrm{CO}_{2}$ and passaged twice a week according to standard procedures.

### 4.5. Cellular uptake studies

For cellular uptake studies, HT-29 and MCF-7 cells were grown until at least $70 \%$ confluency in $175 \mathrm{~cm}^{2}$ cell culture flasks. Stock solutions of complexes 1-11 in DMSO were freshly prepared and diluted with cell culture medium to the desired concentrations (final DMSO concentrations: $0.1 \% \mathrm{v} / \mathrm{v}$, final complex concentration: $1.0-100 \mu \mathrm{M})$. The cell culture medium of the cell culture flasks was replaced with 10 ml of the cell culture medium solutions containing 1-11 and the flasks were incubated for 6 h at $37 \mathrm{C} / 5 \% \mathrm{CO}_{2}$ The cell pellets were isolated, resuspended in $1-5 \mathrm{ml}$ twice distilled water, lysed by using a sonotrode and appropriately diluted using twice distilled water. The rhodium content of the samples was determined by atomic absorption spectroscopy (AAS, see below) and the protein content of separate aliquots by the Bradford method. To correct for matrix effects in AAS measurements, samples and standards were adjusted to the same protein concentration by dilution with twice distilled water (matrix matched

Table 5
Graphite furnace program for AAS measurements

| Step | Temperature $\left({ }^{\circ} \mathrm{C}\right)$ | Ramp $\left({ }^{\circ} \mathrm{C} / \mathrm{s}\right)$ | Hold $(\mathrm{s})$ |
| :--- | :--- | :--- | :--- |
| Drying | 90 | 10 | 40 |
| Drying | 105 | 7 | 30 |
| Drying | 120 | 15 | 20 |
| Drying | 500 | 50 | 30 |
| Pyrolysis | 1200 | 200 | 20 |
| AZ(zeroing) | 1200 | 0 | 6 |
| Atomisation | 2400 | Maximum | 9 |
| Tube cleaning | 2500 | 1000 | 6 |

calibration). Prior to AAS analysis $20 \mu \mathrm{l}$ Triton X-100 (1\%) and $20 \mu \mathrm{l}$ nitric acid acid (13\%) were added to each $200 \mu \mathrm{l}$ sample of the cell suspensions. Cellular uptake was expressed as ng rhodium per mg cell protein for data obtained from two independent experiments.

### 4.6. Atomic absorption spectroscopy

A Vario 6 graphite furnace atomic absorption spectrometer (Analytik Jena) was employed for the Rh quantification using a wavelength of 343.5 nm with a bandpass of 0.5 nm . A deuterium lamp was used for background correction. Matrix containing standards were obtained by addition of a rhodium stock solution $(1 \mathrm{mg} / \mathrm{mL} \mathrm{Rh}$ in $10 \% \mathrm{HCl})$ to untreated cell suspensions. Probes were injected at a volume of $20 \mu$ into standard graphite tubes. Drying, pyrolysis and atomization in the graphite furnace were performed according to the conditions listed in Table 5. During the temperature program the graphite tube was purged with a constant argon gas flow, which was only halted during the zeroing and atomisation steps. Pyrolysis and atomisation temperatures were optimised prior to the experiments. The recovery rates of the metallodrugs were determined initially and used for calculation of the final experimental values. The mean integrated absorbances of duplicate injections were used throughout the study. The characteristical concentration for the described method was $0.85^{ \pm 0.05}\left(\mu \mathrm{~g} \mathrm{Rh} \mathrm{l}^{-1}\right) / 1 \% \mathrm{~A}$.

### 4.7. Cytotoxicity measurements

The antiproliferative effects of the compounds were determined following an established procedure [48]. Cells were suspended in cell culture medium (HT-29: 2850 cells $/ \mathrm{ml}$, MCF-7: $10^{5}$ cells $/ \mathrm{ml}$ ), and $100 \mu \mathrm{l}$ aliquots thereof were plated in 96 well plates and incubated at $37^{\circ} \mathrm{C}$ : $5 \% \mathrm{CO}_{2}$ for 48 h (HT-29) or 72 h (MCF-7). Stock solutions of the compounds in DMSO were freshly prepared and diluted with cell culture medium to the desired concentrations (final DMSO concentration: $0.1 \% \mathrm{v} / \mathrm{v}$ ). The medium in the plates was replaced with medium containing the compounds in graded concentrations (six replicates). After further incubation for 72 h (HT29) or 96 h (MCF-7) the cell biomass was determined by crystal violet staining and the $\mathrm{IC}_{50}$ values were established as those concentrations causing $50 \%$ inhibition of cell proliferation. Results were calculated from 2 to 3 independent experiments.

## Acknowledgements

Financial support of this work in Bochum and Berlin by the Deutsche Forschungsgemeinschaft (DFG) within the research group FOR 630 "Biological function of Organometallic Compounds" is gratefully acknowledged. We are also grateful to Heike MayerFigge and Heike Scheffler for technical support.

## Appendix A. Supplementary material

CCDC 675527, 675528, 675529, 675530, 675531, 675532 and 675533 contain the supplementary crystallographic data for this
paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. Supplementary data associated with this article can be found, in the online version, at doi:10.1016/ j.jorganchem.2008.04.002.

## References

[1] E. Hillard, A. Vessières, F. Le Bideau, D. Plazuk, D. Spera, M. Huche, G. Jaouen, ChemMedChem 1 (2006) 551.
[2] A. Habtemariam, M. Melchart, R. Fernandez, S. Parsons, I.D.H. Oswald, A. Parkin, F.P.A. Fabbiani, J.E. Davidson, A. Dawson, R.E. Aird, D.I. Jodrell, P.J. Sadler, J. Med. Chem. 49 (2006) 6858.
[3] P.J. Dyson, G. Sava, Dalton Trans. (2006) 1929.
[4] A. Vessières, S. Top, W. Beck, E. Hillard, G. Jaouen, Dalton Trans. (2006) 529.
[5] L. Dale, J.H. Tocher, T.M. Dyson, D.I. Edwards, D.A. Tocher, Anti-Cancer Drug Des. 7 (1992) 3.
[6] Y.N. Vashisht Gopal, D. Jayaraju, A.K. Kandapi, Biochemistry 38 (1999) 4382.
[7] Y.N. Vashisht Gopal, N. Konura, A.K. Kandapi, Arch. Biochem. Biophys. 401 (2002) 53.
[8] L.A. Huxham, E.L.S. Cheu, B.O. Patrick, B.R. James, Inorg. Chim. Acta 352 (2003) 238.
[9] C.S. Allardyce, P.J. Dyson, D.J. Ellis, S.L. Heath, Chem. Commun. (2001) 1396.
[10] W.S. Sheldrick, S. Heeb, Inorg. Chim. Acta 168 (1990) 93.
[11] R.E. Morris, R.E. Aird, P.delS. Murdoch, H.M. Chen, J. Cummings, N.D. Hughes, S. Parsons, A. Parkin, G. Boyd, D.I. Jodrell, P.J. Sadler, J. Med. Chem. 44 (2001) 3616.
[12] A.F.A. Peacock, A. Habtemariam, R. Fernández, V. Walland, F.P.A. Fabbiani, S. Parsons, R.E. Aird, D.J. Jodrell, P.J. Sadler, J. Am. Chem. Soc. 128 (2006) 1739.
[13] A.F.A. Peacock, A. Habtemariam, S.A. Moggach, A. Prescimone, S. Parsons, P.J. Sadler, Inorg. Chem. 46 (2007) 4049.
[14] A. Dorcier, W.H. Ang, S. Bolaňo, L. Gonsalvi, L. Juillerat-Jeannerat, G. Laurenczy, M. Peruzzini, A.D. Phillips, F. Zanobini, P.J. Dyson, Organometallics 25 (2006) 4090.
[15] S. Schäfer, I. Ott, R. Gust, W.S. Sheldrick, Eur. J. Inorg. Chem. (2007) 3034.
[16] K.E. Erkkila, D.T. Odom, J.K. Barton, Chem. Rev. 99 (1999) 2777.
[17] C. Metcalfe, J.A. Thomas, Chem. Soc. Rev. 32 (2003) 215.
[18] E.L. Menon, R. Perera, M. Navarro, R.J. Kuhn, H. Morrison, Inorg. Chem. 43 (2004) 5373.
[19] S. Schäfer, W.S. Sheldrick, J. Organomet. Chem. 692 (2007) 1300.
[20] L. Dadci, H. Elias, U. Frey, A. Hörnig, U. Koelle, A.F. Merbach, H. Paulus, J.S. Schneider, Inorg. Chem. 34 (1995) 306.
[21] D.A. Herebian, C.S. Schmidt, W.S. Sheldrick, C. van Wüllen, Eur. J. Inorg. Chem. (1998) 1991.
[22] G. Garcia, G. Sánchez, I. Romero, I. Solano, M.D. Santana, G. Lopez, J. Organomet. Chem. 408 (1991) 241.
[23] U. Kölle, M. Grätzel, Angew. Chem., Int. Ed. Engl. 26 (1987) 507.
[24] U. Kölle, B.-S. Kang, P. Infelta, P. Comte, M. Grätzel, Chem. Ber. 122 (1989) 1869.
[25] M.-T. Youinou, R. Ziessel, J. Organomet. Chem. 363 (1989) 197.
[26] S. Berger, J. Fiedler, R. Reinhardt, W. Kaim, Inorg. Chem. 43 (2004) 1530.
[27] D.A. Herebian, W.S. Sheldrick, J. Chem. Soc., Dalton Trans. (2002) 966.
[28] A. Frodl, D. Herebian, W.S. Sheldrick, J. Chem. Soc., Dalton Trans. (2002) 3664.
[29] S. Gençaslan, W.S. Sheldrick, Eur. J. Inorg. Chem. Soc. (2005) 3840.
[30] D.M. Gray, in: G.D. Fasman (Ed.), Circular Dichroism and the Conformational Analysis of Biomolecules, Plenum Press, New York, 1996, p. 469.
[31] W.C. Johnson, in: N. Berova, K. Nakanishi, R.W. Woody (Eds.), Circular Dichroism: Principles and Applications, 2nd ed., VCH Publishers, New York, 2000, p. 523.
[32] G. Cohen, H. Eisenberg, Biopolymers 4 (1966) 429.
[33] D. Suh, J.B. Chaires, Bioorg. Med. Chem. 3 (1995) 723.
[34] K.K.-W. Lo, C.-K. Chung, N. Zhu, Chem. Eur. J. 12 (2006) 1500.
[35] V.W.-W. Yam, K.K.-W. Lo, K.-K. Cheung, R.Y.-C. Kong, J. Chem. Soc., Dalton Trans. (1997) 2067.
[36] K.K.-W. Lo, R.Y.-C. Kong, Organometallics 23 (2004) 3062.
[37] S.P. Foxon, C. Metcalfe, H. Adams, M. Webb, J.A. Thomas, Inorg. Chem. 46 (2007) 409.
[38] J. Sartorius, H.-J. Schneider, J. Chem. Soc., Perkin Trans. 2 (1997) 2319.
[39] A. Raja, V. Rajendrian, P. Uma Masheswari, R. Balamunrugam, C.A. Kilner, M.A. Halcrow, M. Palaniandavar, J. Inorg. Biochem. 99 (2005) 1717.
[40] B. Selvakumar, V. Rajendrian, P. Uma Masheswari, H. Stoecki-Evans, M. Palaniandavar, J. Inorg. Biochem. 100 (2006) 316.
[41] M. Scharwitz, I. Ott, R. Gust, A. Kromm, W.S. Sheldrick, J. Inorg. Biochem. (2008), doi:10.1016/j.jinorgbio.2008.03.001.
[42] J.S. Ren, T.C. Jenkins, J.B. Chaires, Biochemistry 39 (2000) 8439.
[43] J.W. Kang, K. Moseley, P.M. Maitlis, J. Am. Chem. Soc. 91 (1969) 5970.
[44] J.G. Collins, A.D. Sleemann, J.R. Aldrich-Wright, I. Greguric, T.W. Hambley, Inorg. Chem. 37 (1998) 3133.
[45] A. Delgadillo, P. Romo, A.M. Leiva, B. Loeb, Helv. Chim. Acta 86 (2003) 2110.
[46] G.M. Sheldrick, SHELxs97 and shelxl 97, Göttingen, Germany, 1997.
[47] J. Marmur, J. Mol. Biol. 3 (1961) 208.
[48] I. Ott, K. Schmidt, B. Kircher, P. Schuhmacher, T. Wiglenda, R. Gust, J. Med. Chem. 48 (2005) 622.


[^0]:    * Corresponding author. Tel.: +49 2343224192 ; fax: +49 2343214420.

    E-mail address: william.sheldrick@rub.de (W.S. Sheldrick).

[^1]:    ${ }^{\text {a }}$ Towards the human cancer cell lines MCF-7 (breast cancer) and HT-29 (colon cancer); the values in brackets represent the standard errors.

